Global Tourette syndrome Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Tourette syndrome treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Abide Therapeutics Inc, Catalyst Pharmaceuticals Inc, Emalex Biosciences Inc, Genco Sciences LLC , KemPharm Inc and others.
A Significant contribution to the Tourette syndrome pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Tourette syndrome pipeline included 9 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Tourette syndrome condition and increased access to investments is encouraging growth of Tourette syndrome drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Tourette syndrome drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Tourette syndrome therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Tourette syndrome pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Tourette syndrome. Further, orphan drug status, fast track designation, grants awarded and other special status for Tourette syndrome pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Tourette syndrome pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Tourette syndrome Pipeline candidates-
A Significant contribution to the Tourette syndrome pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Tourette syndrome pipeline included 9 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Tourette syndrome condition and increased access to investments is encouraging growth of Tourette syndrome drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Tourette syndrome drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Tourette syndrome therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Tourette syndrome pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Tourette syndrome. Further, orphan drug status, fast track designation, grants awarded and other special status for Tourette syndrome pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Tourette syndrome pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Tourette syndrome Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Tourette syndrome drugs
- Late phase: Phase 3 and in-approval Tourette syndrome drugs
- Company overview
- Snapshot
- Tourette syndrome therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Tourette syndrome- Disease Overview
2.2 Tourette syndrome- Pipeline Snapshot
2.3 Tourette syndrome- Pipeline Drugs by Phase
2.4 Tourette syndrome- Pipeline Drugs by Company
2.5 Tourette syndrome- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abide Therapeutics Inc Tourette syndrome Drug Pipeline, H2- 2019
3.2 Catalyst Pharmaceuticals Inc Tourette syndrome Drug Pipeline, H2- 2019
3.3 Emalex Biosciences Inc Tourette syndrome Drug Pipeline, H2- 2019
3.4 Genco Sciences LLC Tourette syndrome Drug Pipeline, H2- 2019
3.5 KemPharm Inc Tourette syndrome Drug Pipeline, H2- 2019
3.6 Neurocrine Biosciences Inc Tourette syndrome Drug Pipeline, H2- 2019
3.7 SOM Biotech SL Tourette syndrome Drug Pipeline, H2- 2019
3.8 Teva Pharmaceutical Industries Ltd Tourette syndrome Drug Pipeline, H2- 2019
3.9 Therapix Biosciences Ltd Tourette syndrome Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Tourette syndrome- Phase 1 Drug Details
4.2 Tourette syndrome- Phase 1 Drug Overview
4.3 Tourette syndrome- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Tourette syndrome- Phase 2 Drug Details
5.2 Tourette syndrome- Phase 2 Drug Overview
5.3 Tourette syndrome- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Tourette syndrome- Phase 3 Drug Details
6.2 Tourette syndrome- Phase 3 Drug Overview
6.3 Tourette syndrome- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Tourette syndrome- Pre-clinical Phase Drug Details
7.2 Tourette syndrome- Pre-clinical Phase Drug Overview
7.3 Tourette syndrome- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Tourette syndrome- Disease Overview
2.2 Tourette syndrome- Pipeline Snapshot
2.3 Tourette syndrome- Pipeline Drugs by Phase
2.4 Tourette syndrome- Pipeline Drugs by Company
2.5 Tourette syndrome- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abide Therapeutics Inc Tourette syndrome Drug Pipeline, H2- 2019
3.2 Catalyst Pharmaceuticals Inc Tourette syndrome Drug Pipeline, H2- 2019
3.3 Emalex Biosciences Inc Tourette syndrome Drug Pipeline, H2- 2019
3.4 Genco Sciences LLC Tourette syndrome Drug Pipeline, H2- 2019
3.5 KemPharm Inc Tourette syndrome Drug Pipeline, H2- 2019
3.6 Neurocrine Biosciences Inc Tourette syndrome Drug Pipeline, H2- 2019
3.7 SOM Biotech SL Tourette syndrome Drug Pipeline, H2- 2019
3.8 Teva Pharmaceutical Industries Ltd Tourette syndrome Drug Pipeline, H2- 2019
3.9 Therapix Biosciences Ltd Tourette syndrome Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Tourette syndrome- Phase 1 Drug Details
4.2 Tourette syndrome- Phase 1 Drug Overview
4.3 Tourette syndrome- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Tourette syndrome- Phase 2 Drug Details
5.2 Tourette syndrome- Phase 2 Drug Overview
5.3 Tourette syndrome- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Tourette syndrome- Phase 3 Drug Details
6.2 Tourette syndrome- Phase 3 Drug Overview
6.3 Tourette syndrome- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Tourette syndrome- Pre-clinical Phase Drug Details
7.2 Tourette syndrome- Pre-clinical Phase Drug Overview
7.3 Tourette syndrome- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
